Lytix Biopharma ASA (LYTIX.OL)
Oslo · NOK · Healthcare · Biotechnology
NOK 7.88 (+0.25%) as of
Key statistics
- Market cap
- 605.97M
- Forward P/E
- -5.79
- EPS (TTM)
- -1.33
- Dividend yield
- 0.00%
- 52-week range
- 7.24 – 11.90
- Beta
- -0.53
- Profit margin
- 0.00%
- Analyst target
- NOK 15.00
- Volume
- 19.69k
About Lytix Biopharma ASA
Lytix Biopharma ASA, a clinical stage biotech company, develops novel cancer immunotherapies for cancer therapy in the United States. Its lead product candidate is ruxotemitide, an oncolytic molecule that is developed for intratumoral injections, which is in Phase III clinical trials, to treat melanoma, basal cell carcinoma, and advanced soft tissue sarcoma; and NeoLIPA Phase II study in combination with pembrolizumab. The company also offers LTX-401, an oncolytic molecule in preclinical phase for the treatment of deep-seated tumors, such as hepatocellular carcinoma in liver cancer and liver metastases. It has a partnership with Verrica Pharmaceuticals Inc. for the development and commercialization of ruxotemitide for the treatment of all malignant and pre-malignant dermatological indications. Lytix Biopharma ASA was founded in 2003 and is based in Oslo, Norway.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Oslo, Norway
- Employees
- 14
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.